What do systematic reviews say?

First‐line beta‐blocker vs placebo

First‐line beta‐blocker showed no clear difference in total mortality compared with placebo (moderate certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.96 [0.86, 1.07]
  5 studies · 19313 participants
  Moderate

First‐line beta‐blocker vs placebo

First‐line beta‐blocker may leads to lower total stroke compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.83 [0.72, 0.97]
  5 studies · 19313 participants
  Low

First‐line beta‐blocker vs placebo

First‐line beta‐blocker showed no clear difference in total coronary heart disease compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.9 [0.78, 1.03]
  5 studies · 19313 participants
  Low

First‐line beta‐blocker vs placebo

First‐line beta‐blocker may leads to lower total cardiovascular events compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.89 [0.81, 0.98]
  5 studies · 19313 participants
  Low

First‐line beta‐blocker vs placebo

First‐line beta‐blocker may leads to higher withdrawal due to adverse effects compared with placebo (low certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 4.59 [4.11, 5.13]
  4 studies · 18565 participants
  Low

First‐line thiazides vs beta‐blocker

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 18241 participants
  Moderate

First‐line thiazides vs beta‐blocker

The review found no eligible studies for this question.

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

First‐line thiazides vs beta‐blocker

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 18135 participants
  Moderate

First‐line thiazides vs beta‐blocker

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 18135 participants
  Low

First‐line thiazides vs beta‐blocker

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 18135 participants
  Low

First‐line thiazides vs beta‐blocker

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 6569 participants
  Low

First‐line thiazides vs beta‐blocker

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 18501 participants
  Moderate

RAS inhibitors vs beta‐blocker

RAS inhibitors showed no clear difference in all‐cause death compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 0.89 [0.78, 1.01]
  1 study · 9193 participants
  Low

RAS inhibitors vs beta‐blocker

RAS inhibitors may leads to lower total cardiovascular events compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 0.88 [0.8, 0.98]
  2 studies · 9239 participants
  Low

RAS inhibitors vs beta‐blocker

RAS inhibitors showed no clear difference in total heart failure compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 0.95 [0.76, 1.18]
  1 study · 9193 participants
  Low

RAS inhibitors vs beta‐blocker

RAS inhibitors showed no clear difference in total myocardial infarction compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 1.05 [0.86, 1.27]
  2 studies · 9239 participants
  Low

RAS inhibitors vs beta‐blocker

RAS inhibitors may leads to lower total stroke compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 0.75 [0.63, 0.88]
  1 study · 9193 participants
  Low